Ascendis Pharma A/S is a Danish biotechnology company focused on the development and commercialization of therapeutic solutions for rare diseases and endocrine disorders. Founded in 2006, its innovative approach utilizes the proprietary TransCon™ technology, enabling targeted and long-acting drug delivery. The company specializes in developing medications that provide continuous release of active ingredients into the body, improving effectiveness and patient convenience. Its main therapeutic areas include growth hormone disorders, hypoparathyroidism, and other endocrine diseases. Ascendis Pharma has a global reach, with its products in various stages of clinical development.